Learn More About Global Compliance
Stay updated with what’s happening in the world of aggregate spend and global compliance using the MediSpend Aggregate Spend Resource Center. Here you’ll find a collection of reports, documents, maps, and other resources that have been complied by our Team of Global Compliance and Aggregate Spend Experts.
Active Legislation
Social Security Act 1128G (Sunshine Act)
Transparency Reports and Reporting of Physician Ownership or Investment Interests [114]
Sec. 1128G. [42 U.S.C. 1320a-7h] (a) Transparency Reports.
This legislation specifies what information manufacturers must include in their reports. This legislation covers “payments or other transfers of value.”
Nevada: Assembly Bill 128, Statutes of Nevada Chapter 409
AB 128, Statutes of Nevada Chapter 409 (effective October 1, 2007) requires that all wholesalers or manufacturers who employ a person to sell or market a drug, medicine, chemical, device, or appliance in Nevada must comply with certain requirements regarding their marketing practices. On January 30, 2008, regulations promulgated by the Nevada State Board of Pharmacy to implement AB 128 became effective.
Connecticut: APRN Disclosure Law
AN ACT CONCERNING REPORTING OF PAYMENTS BY MANUFACTURERS TO INDEPENDENTLY-PRACTICING ADVANCED PRACTICE REGISTERED NURSES.
Not later than July 1, [2015] 2017, and [quarterly] annually thereafter, an applicable manufacturer that provides a payment or other transfer of value to an advanced practice registered nurse, who is practicing not in collaboration with a physician in the state, in accordance with subsection (b) of section 20-87a, as amended by this act, shall submit to the Commissioner of Consumer Protection, in the form and manner prescribed by the commissioner, the information described in 42 USC 1320a-7h, as amended from time to time, for the preceding calendar year.
California: CA HSC § 119400-119402
HEALTH AND SAFETY CODE SECTION 119400-119402
Every pharmaceutical company shall adopt a Comprehensive Compliance Program that is in accordance with the April
2003 publication “Compliance Program Guidance for Pharmaceutical Manufacturers,” which was developed by the United States Department of Health and Human Services Office of Inspector General (OIG).
Documents
MediSpend Global Compliance Platform brochure
A comprehensive cloud-based aggregate spend tracking and reporting compliance solution designed specifically for Pharmaceutical and Medical Device companies.
MediSpend Federal Brochure
Supports small- to mid-sized companies in the life sciences industry by automating Open Payments submissions with a robust, rules-based federal reporting system backed by a database of more than 18 million HCP records.
The Evolution of Corporate Compliance: The Road From Reactive to Proactive
Interpreting the OIG’s 7 Original Elements and their new RAMP Guidelines
MediSpend Engagement Manager Brochure
An HCP engagement and management solution designed to minimize risk and maximize compliance by substantiating a business need, qualifying HCPs, establishing FMV and documenting all activities.
Analysis of Proposed Rules in Support of the PPACA
On December 19, 2011, the Centers for Medicare & Medicaid Services (CMS) published the proposed rule implementing the transparency provisions set forth at section 6002 of the Patient Protection and Affordable Care Act (PPACA).
MediSpend Insight Brochure
Data analysis dashboards for compliance monitoring, risk assessment and business analytics.
MediSpend
MediSpend Notification Center Brochure
A direct access point for physicians and HCOs to confirm and dispute all spend information being reported to the Federal government.
